scholarly journals Corneal confocal microscopy detects corneal nerve damage and increased dendritic cells in Fabry disease

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Gulfidan Bitirgen ◽  
Kultigin Turkmen ◽  
Rayaz A. Malik ◽  
Ahmet Ozkagnici ◽  
Nazmi Zengin
Stroke ◽  
2017 ◽  
Vol 48 (11) ◽  
pp. 3012-3018 ◽  
Author(s):  
Adnan Khan ◽  
Naveed Akhtar ◽  
Saadat Kamran ◽  
Georgios Ponirakis ◽  
Ioannis N. Petropoulos ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jeremy Chung Bo Chiang ◽  
David Goldstein ◽  
Azadeh Tavakoli ◽  
Terry Trinh ◽  
Jacob Klisser ◽  
...  

AbstractImmune cell infiltration has been implicated in neurotoxic chemotherapy for cancer treatment. However, our understanding of immune processes is still incomplete and current methods of observing immune cells are time consuming or invasive. Corneal dendritic cells are potent antigen-presenting cells and can be imaged with in-vivo corneal confocal microscopy. Corneal dendritic cell densities and nerve parameters in patients treated with neurotoxic chemotherapy were investigated. Patients treated for cancer with oxaliplatin (n = 39) or paclitaxel (n = 48), 3 to 24 months prior to assessment were recruited along with 40 healthy controls. Immature (ImDC), mature (MDC) and total dendritic cell densities (TotalDC), and corneal nerve parameters were analyzed from in-vivo corneal confocal microscopy images. ImDC was increased in the oxaliplatin group (Median, Md = 22.7 cells/mm2) compared to healthy controls (Md = 10.1 cells/mm2, p = 0.001), but not in the paclitaxel group (Md = 10.6 cells/mm2). ImDC was also associated with higher oxaliplatin cumulative dose (r = 0.33, p = 0.04) and treatment cycles (r = 0.40, p = 0.01). There was no significant difference in MDC between the three groups (p > 0.05). Corneal nerve parameters were reduced in both oxaliplatin and paclitaxel groups compared to healthy controls (p < 0.05). There is evidence of elevation of corneal ImDC in oxaliplatin-treated patients. Further investigation is required to explore this potential link through longitudinal studies and animal or laboratory-based immunohistochemical research.


PLoS ONE ◽  
2020 ◽  
Vol 15 (4) ◽  
pp. e0231987
Author(s):  
Adnan Khan ◽  
Naveed Akhtar ◽  
Saadat Kamran ◽  
Hamad Almuhannadi ◽  
Georgios Ponirakis ◽  
...  

Diabetes Care ◽  
2013 ◽  
Vol 36 (11) ◽  
pp. 3646-3651 ◽  
Author(s):  
I. N. Petropoulos ◽  
U. Alam ◽  
H. Fadavi ◽  
O. Asghar ◽  
P. Green ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yuanjin Zhang ◽  
Dongsheng Fan ◽  
Yixuan Zhang ◽  
Shuo Zhang ◽  
Haikun Wang ◽  
...  

AbstractThis randomized controlled study used corneal confocal microscopy (CCM) to compare the efficacy of Mecobalamin intramuscular injections vs oral tablets in treating mild to moderate diabetic peripheral neuropathy (DPN) by detecting early nerve fiber repair. Enrolled patients were randomized approximately 1:1 to receive Mecobalamin intramuscular injections (0.5 mg/day, 3 times/week) or Mecobalamin oral tablets (1.5 mg/day) for 8 weeks. Primary outcome was change of inferior whorl length (IWL) from baseline. Secondary outcomes included changes of corneal nerve fibre length (CNFL), corneal nerve fibre density (CNFD), corneal nerve branch density (CNBD) and the Survey of Autonomic Symptoms (SAS). 15 (93.75%) patients in the injection group and 17 (89.47%) patients in the tablet group completed the study. The injection treatment significantly improved patients’ IWL from baseline (21.64 ± 3.00 mm/mm2 vs 17.64 ± 4.83 mm/mm2, P < 0.01) while the tablet treatment didn’t. Additionally, the injection treatment led to significantly improved CNFL, CNBD and SAS from baseline (all P < 0.05) while the tablet treatment did not. No patient experienced any adverse events. In conclusion, CCM is sensitive enough to detect the superior efficacy of 8-week Mecobalamin intramuscular injection treatment for DPN compared to the oral tablet treatment.ClinicalTrials.gov registration number: NCT04372316 (30/04/2020).


Cornea ◽  
2000 ◽  
Vol 19 (Supplement 2) ◽  
pp. S131
Author(s):  
T Tervo ◽  
T U Valle ◽  
J AO Moilanen ◽  
M E Rosenberg ◽  
I SJ Tuominen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document